A widely available over-the-counter artificial tears product has been linked to four deaths, fourteen cases of permanent vision loss, and four surgical eye removals across the United States. The products at the center of this crisis — EzriCare Artificial Tears and Delsam Pharma Artificial Tears, both manufactured by Global Pharma Healthcare in Chennai, India — were contaminated with an extensively drug-resistant strain of Pseudomonas aeruginosa that had never before been identified in the country. The FDA recalled the products in February 2023 after the CDC issued a public health alert, but the damage to dozens of patients was already done.
By May 2023, the CDC had identified 81 patients across 18 states suffering from infections tied to the contaminated drops. The states affected ranged from California to Florida, New York to Texas, and many points in between. For older adults, particularly those managing dementia or other cognitive conditions, this outbreak carries an added layer of concern: eye drops are among the most commonly used over-the-counter products in senior care, and individuals with cognitive decline may not be able to report symptoms of infection in time for early treatment. This article examines how the contamination happened, what the FDA found during its investigation, the broader recall that followed, and what caregivers should know to protect vulnerable loved ones.
Table of Contents
- What Contaminated Eye Drops Are Blinding People and Why Is the FDA Investigating?
- How Manufacturing Failures Led to a Deadly Contamination
- The Broader Eye Drop Recall That Followed
- What Caregivers of Dementia Patients Should Do Right Now
- Why Drug-Resistant Infections Are Especially Dangerous for Older Adults
- Legal Actions and What Affected Families Should Know
- What This Crisis Means for Over-the-Counter Drug Safety Going Forward
- Conclusion
- Frequently Asked Questions
What Contaminated Eye Drops Are Blinding People and Why Is the FDA Investigating?
The bacteria found in the contaminated eye drops was Pseudomonas aeruginosa sequence type ST-1203, carrying two resistance genes — blaVIM-80 and blaGES-9 — a combination that had never been detected in the United States before this outbreak. This made the organism extensively drug-resistant, meaning it could withstand carbapenem antibiotics, which are typically considered a last line of defense against serious bacterial infections. When patients developed eye infections from the contaminated drops, doctors found themselves with severely limited treatment options. The drops were sold in multi-use bottles without adequate preservatives, which created an environment where bacteria could grow between uses. Unlike single-use vials that are opened, applied, and discarded, multi-use bottles are repeatedly opened and closed over days or weeks.
Without proper preservative formulation and sterile manufacturing, each use becomes an opportunity for microbial contamination to multiply. For comparison, most major-brand artificial tears sold in multi-use bottles contain benzalkonium chloride or similar preservatives specifically to prevent this kind of bacterial growth — the Global Pharma products lacked these safeguards. The infections did not remain confined to the eyes. Four patients died from bloodstream infections after the bacteria spread beyond the initial site of contact. This progression from a seemingly minor eye drop application to a fatal systemic infection underscores how dangerous drug-resistant organisms can be, especially in older or immunocompromised individuals. Bloodstream infections from Pseudomonas aeruginosa carry high mortality rates even when the strain is susceptible to antibiotics; when the strain resists frontline treatments, the prognosis worsens dramatically.
How Manufacturing Failures Led to a Deadly Contamination
The fda inspected Global Pharma Healthcare’s manufacturing facility in India and found conditions that read like a checklist of what not to do in pharmaceutical production. Inspectors documented unsanitary conditions, dirty equipment, a complete absence of microbial testing on finished products, and no tamper-evident packaging controls. These are not minor technical violations — they represent a fundamental breakdown in the Current Good Manufacturing Practice (CGMP) standards that exist specifically to prevent contaminated products from reaching patients. On October 20, 2023, the FDA issued a formal warning letter to Global Pharma Healthcare citing multiple CGMP violations. The agency also placed the company under an import alert, effectively banning all products from Global Pharma from entering the United States. Indian regulators followed suit and halted eye product production at the facility.
However, it is worth noting that the damage from products already distributed had been unfolding for months before these enforcement actions took effect. If you or a loved one purchased EzriCare or Delsam Pharma Artificial Tears before the recall, those bottles should have been discarded immediately — and if any remain in a medicine cabinet, they must be thrown away now. The case highlights a persistent vulnerability in the U.S. pharmaceutical supply chain. Many over-the-counter products are manufactured overseas, and FDA inspections of foreign facilities happen far less frequently than inspections of domestic ones. For caregivers overseeing medication regimens for people with dementia, this is a sobering reminder that “FDA-approved” or “sold in the U.S.” does not automatically guarantee that every product on a pharmacy shelf has been manufactured under rigorous conditions.
The Broader Eye Drop Recall That Followed
The contamination crisis did not end with EzriCare and Delsam Pharma. In October 2023, the FDA warned consumers to stop using 26 additional over-the-counter eye drop products sold at major retailers including CVS, Rite Aid, Walmart, and Target due to infection risk. These were separate products from different manufacturers, but the FDA determined they also posed safety concerns related to contamination or manufacturing deficiencies. In total, more than 200 potentially unsafe eye drop products have been reported to the FDA. This wave of recalls shook consumer confidence in a product category that most people consider completely benign.
Artificial tears are not a niche product — millions of Americans use them daily for dry eye, allergies, or post-surgical care. For dementia patients in particular, dry eyes are a common complaint, sometimes worsened by medications like cholinesterase inhibitors or by reduced blink rates associated with cognitive decline. Caregivers who had been routinely administering eye drops suddenly faced the question of whether the specific product in their care supplies was safe. One specific example illustrates the scope of the problem: some of the recalled products were store-brand versions sold under familiar pharmacy labels, making them appear just as trustworthy as name-brand options. A caregiver picking up artificial tears at a national chain pharmacy would have had no reason to suspect a problem. The FDA’s recall list became essential reading for anyone purchasing eye drops, and it remains a resource worth checking before buying unfamiliar brands.
What Caregivers of Dementia Patients Should Do Right Now
The first and most important step for anyone caring for an older adult is to check every eye drop bottle in the household against the FDA’s recall list. This includes products stored in bedside drawers, bathroom cabinets, travel bags, and purses. Dementia patients may have bottles stashed in unexpected places, and a single application from a contaminated product can introduce dangerous bacteria. When replacing recalled or questionable products, caregivers face a tradeoff between preservative-free single-use vials and preserved multi-use bottles. Single-use vials eliminate the risk of bacterial growth between applications because each vial is opened, used once, and discarded.
However, they are more expensive and generate more waste, and the small vials can be difficult for arthritic hands to open. Preserved multi-use bottles from established manufacturers with strong safety records remain a reasonable option — the key is choosing products from companies with transparent manufacturing practices and verifiable quality controls, not the cheapest available option. Brands manufactured domestically or in countries with robust regulatory oversight carry lower risk, though no option is completely without risk. For dementia patients who cannot reliably report eye discomfort, redness, or changes in vision, caregivers should perform regular visual checks of the eyes before and after administering drops. Any signs of redness, swelling, discharge, or unusual sensitivity to light should prompt an immediate call to the patient’s ophthalmologist. Early detection of an eye infection can mean the difference between a treatable condition and permanent vision loss.
Why Drug-Resistant Infections Are Especially Dangerous for Older Adults
The Pseudomonas aeruginosa strain found in the contaminated eye drops was not just any bacterium — it was extensively drug-resistant, meaning most available antibiotics could not kill it. For older adults, particularly those with dementia who may already have compromised immune function, weakened nutritional status, or multiple comorbidities, drug-resistant infections represent an outsized threat. Their bodies are less equipped to fight off infections even with pharmaceutical support, and when the pharmaceutical options are limited by resistance, outcomes worsen considerably. There is a broader warning here that extends beyond this specific outbreak. The World Health Organization has identified antimicrobial resistance as one of the top global public health threats, and contaminated consumer products represent an underappreciated vector for introducing resistant organisms into communities.
A person with dementia living in a care facility who develops a drug-resistant Pseudomonas infection does not just face personal danger — they can become a source of transmission to other vulnerable residents. Caregivers should understand that symptoms of a serious eye infection may present differently in dementia patients. A cognitively intact person would likely report pain, blurred vision, or sensitivity to light. A person with moderate to advanced dementia may instead become agitated, rub their eyes repeatedly, refuse to open their eyes, or simply withdraw. These behavioral changes can be mistakenly attributed to the progression of dementia itself, delaying diagnosis and treatment of the underlying infection.
Legal Actions and What Affected Families Should Know
Multiple injury and class action lawsuits have been filed against EzriCare, Delsam Pharma, and Global Pharma Healthcare by patients who suffered infections, vision loss, or lost family members. As of early 2026, no multidistrict litigation has been established, and no settlements or jury trials have been scheduled. Reports suggest that potential settlement talks may be underway, but no amounts have been announced.
Families affected by the contaminated eye drops who have not yet consulted an attorney should consider doing so, as statutes of limitations on personal injury claims vary by state and may begin running from the date of injury or the date the injury was discovered. For caregivers who administered the contaminated drops to a dementia patient, the situation carries an additional emotional weight. Many feel guilt despite having done nothing wrong — they used an FDA-cleared product purchased from a legitimate retailer. The responsibility lies squarely with the manufacturer that failed to maintain basic sanitary standards, not with the caregiver who trusted a product that should have been safe.
What This Crisis Means for Over-the-Counter Drug Safety Going Forward
This outbreak has already prompted calls for stronger FDA oversight of foreign pharmaceutical manufacturing facilities and for stricter requirements around preservative systems in multi-use ophthalmic products. Whether those calls translate into regulatory action remains to be seen. The FDA’s import alert against Global Pharma Healthcare was a decisive step, but the broader finding of more than 200 potentially unsafe eye drop products on the U.S. market suggests the problem extends well beyond a single manufacturer.
For families navigating dementia care, the lesson is both specific and general. Specifically, check every eye drop product against current FDA recall lists before use. More generally, maintain a healthy skepticism toward the assumption that every product on a pharmacy shelf has been rigorously tested and safely manufactured. Keep a running list of all products used in a loved one’s care, stay alert to FDA safety communications, and never hesitate to ask a pharmacist or physician about the safety profile of a specific brand.
Conclusion
The contaminated EzriCare and Delsam Pharma artificial tears outbreak — with 81 infections, four deaths, fourteen cases of permanent vision loss, and four enucleations across 18 states — stands as one of the most alarming over-the-counter drug safety failures in recent memory. The extensively drug-resistant Pseudomonas aeruginosa strain at the heart of the crisis was introduced through manufacturing negligence at a facility in India that the FDA found riddled with sanitary violations, absent microbial testing, and no tamper-evident controls. The subsequent discovery that more than 200 additional eye drop products may also be unsafe has only widened the scope of concern.
For caregivers of people living with dementia, vigilance around seemingly routine products like eye drops is now a non-negotiable part of safe care. Check current recall lists, choose products from reputable manufacturers, opt for single-use vials when feasible, and monitor your loved one’s eyes regularly for any signs of infection. If a dementia patient shows unexplained behavioral changes — agitation, eye rubbing, refusal to open their eyes — consider an eye infection as a possible cause and seek medical attention promptly. The products that were supposed to provide comfort should never become a source of harm, and informed caregiving is the strongest line of defense.
Frequently Asked Questions
Are EzriCare Artificial Tears still being sold?
No. EzriCare Artificial Tears were recalled in February 2023 and Global Pharma Healthcare has been placed under an FDA import alert banning all of its products from entering the United States. However, bottles purchased before the recall may still exist in homes or care facilities and should be discarded immediately.
How do I check if my eye drops have been recalled?
Visit the FDA’s drug recalls page and search for your specific product. The FDA issued warnings about EzriCare, Delsam Pharma, and 26 additional over-the-counter eye drop products sold at CVS, Rite Aid, Walmart, and Target. If you are unsure about a specific brand, contact your pharmacist.
What are the symptoms of a Pseudomonas eye infection?
Symptoms typically include eye redness, pain, swelling, discharge (often yellow-green), blurred vision, and sensitivity to light. In dementia patients who cannot verbalize these symptoms, watch for behavioral changes such as increased agitation, repeated eye rubbing, refusal to open the eyes, or withdrawal from activities.
Can I still use artificial tears safely?
Yes. Artificial tears from established, reputable manufacturers with proper preservative systems remain safe for most people. Single-use preservative-free vials carry the lowest contamination risk. Always check the FDA recall list before purchasing, and discard any bottle that appears damaged, discolored, or past its expiration date.
Is there a lawsuit I can join if my family member was affected?
Multiple lawsuits have been filed against EzriCare, Delsam Pharma, and Global Pharma Healthcare. As of early 2026, no multidistrict litigation or settlements have been established. Consult a personal injury attorney in your state to discuss your specific situation, as statutes of limitations vary.
Are eye drops manufactured in the U.S. safer than imported ones?
Domestic manufacturing does not automatically guarantee safety, but FDA inspections of U.S. facilities occur more frequently than inspections of overseas plants. The contamination in this case originated from a facility in India where basic manufacturing standards were not being followed. Choosing products from manufacturers with established track records and transparent quality controls reduces risk regardless of where they are made.
